Among CNS tumors, MYB or MYBL1 alterations are noted in the current World Health Organization (WHO) classification as 2 tumor types: “Angiocentric glioma” and “Diffuse astrocytoma, MYB- or MYBL1-altered,” both as WHO grade 1 [1, 3, 7]. This evidence concerns the gene MYB and central nervous system neoplasm.